Thor Nagel

Thor Nagel is an Analyst at BVF Partners, L.P., a San Francisco-based investment firm specializing in biotechnology and healthcare sectors. In this role, he conducts in-depth equity research and provides investment recommendations focusing primarily on life sciences and innovative healthcare companies, supporting the firm’s long-standing expertise in these asset classes.

Prior to joining BVF Partners in 2023, Thor held the position of Senior Analyst at Monashee Investment Management LLC, where he was responsible for investment analysis within the finance and healthcare sectors, and previously served as Associate II at Stifel Financial Corp., gaining experience in financial services and commercial markets. He also held analytical roles at Clearview Healthcare Partners, deepening his expertise in the biotech, pharma, and medical device industries.

Thor holds a Master of Science in Engineering, Science, and Technology Entrepreneurship from the University of Notre Dame and a Bachelor’s Degree in Chemical Engineering from Vanderbilt University. His educational and professional background have contributed to a specialized focus on public equities in biotechnology, making him a valuable contributor to healthcare-focused investment strategies.